Evidence map›Paper›PMID 41501244›Full record

ArticleScientific reports2026

Exploring the chemodiversity of antimicrobial minalemines from Didemnum granulatum by neutral loss graph.

Vítor F Freire, Jason R Evans, Lucero Martínez-Fructuoso, Rohitesh Kumar, Rhone K Akee, Svetlana Hogan, Christopher C Thornburg, Brian D Peyser, Susan Ensel, Dongdong Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vítor F FreireNatural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, 21702-1201, USA. vitor.freire@nih.gov.
Jason R EvansNatural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, 21702-1201, USA.
Lucero Martínez-FructuosoNatural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, 21702-1201, USA.
Rohitesh KumarNatural Products Support Group, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702-1201, USA.
Rhone K AkeeNatural Products Support Group, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702-1201, USA.
Svetlana HoganNatural Products Support Group, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702-1201, USA.
Christopher C ThornburgNatural Products Support Group, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702-1201, USA.
Brian D PeyserNatural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, 21702-1201, USA.
Susan EnselNatural Products Support Group, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, 21702-1201, USA.
Dongdong WangMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702-1201, USA.
Tanja GrkovicNatural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, 21702-1201, USA.
Barry R O'KeefeNatural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, 21702-1201, USA. okeefeba@mail.nih.gov.

Funding

NCI Program for Natural Products Discovery - CuresZIABC011854 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2020 to 2025
$5.2M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011854NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

In this study, we report on the identification of the active antimicrobial principles from the tunicate Didemnum granulatum. Two new natural products, minalemines G (1) and H (2), were isolated and their structures were elucidated. Both compounds showed potent antibacterial activity, with compound 1 showing sub-microgram inhibition against Staphylococcus aureus. Moreover, we also report a new mass spectrometry-based approach, named neutral loss graph, developed to explore minor metabolites from complex mixtures. This approach was applied here to reveal twelve additional minalemine analogues in the organic extract of D. granulatum.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsUrochordataAnimalsMass SpectrometryMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial AgentsAnti-Infective Agents

Identifiers

PMID41501244
PMCPMC12816755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.